| Pharmaceutical Information |
| Drug Name |
Atosiban |
| Drug ID |
BADD_D00185 |
| Description |
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. |
| Indications and Usage |
|
| Marketing Status |
Not Available |
| ATC Code |
G02CX01 |
| DrugBank ID |
DB09059
|
| KEGG ID |
D03008
|
| MeSH ID |
C047046
|
| PubChem ID |
5311010
|
| TTD Drug ID |
D0D8XY
|
| NDC Product Code |
Not Available |
| Synonyms |
atosiban | (Mpa(1)-D-Tyr(Et)(2)-Thr(4)-Orn(8))-oxytocin | oxytocin, 1-deamino-O-ethyltyrosyl(2)-threonyl(4)-ornithine(8)- | oxytocin, 1-deamino-(O-Et-Tyr)(2)-Thr(4)-Orn(8)- | (Mpa(1),D-Tyr(Et)2,Thr(4),Orn(8))oxytocin | 1-deamino-2-Tyr(OEt)-4-Thr-8-Orn-oxytocin | RWJ-22164 | RWJ 22164 | ORF-22164 | ORF 22164 |
|
| Chemical Information |
| Molecular Formula |
C43H67N11O12S2 |
| CAS Registry Number |
90779-69-4 |
| SMILES |
CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CC
CC3C(=O)NC(CCCN)C(=O)NCC(=O)N)CC(=O)N)C(C)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Mental disorder | 19.07.01.002 | - | - | Not Available |
|
|
|
